AI in SK Histopathological Diagnosis

计划入组 30 人 · 首次发布于 2026 年 8 月 26 日

A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403

计划入组 30 人 · 首次发布于 2010 年 5 月 26 日

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

计划入组 35 人 · 首次发布于 2013 年 11 月 19 日

p300 Degrading(SK Life Science)

SMARCA2 degrader(SK Life Science)

p300 degraders therapy(SK Life Science Labs)

SK Life Science, Inc.

United States

DENA LIFE SCIENCE, INC.

Japan

Arena Life Science

SK Life Science to Present Comprehensive Cenobamate Data and Patient-Provider Communication Study at AAN 2026

SK Biopharmaceuticals Acquires Full Control of U.S. R&D Unit with $36 Million Investment to Advance Cancer Pipeline

Clinical Trials Offer Hope for Children and Teens with Uncontrolled Seizures